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Merissa Zeman, Ethan Silver and Esma Akin*
Department of Radiology, George Washington University Hospital, USA

Abstract
As urachal adenocarcinomas are rare cancers, experience with diagnosing and staging them are
limited. To help illustrate CT and PET imaging findings and the role they each play in the workup of
urachal adenocarcinomas, we present the case of a 43 y.o. male who was diagnosed at our institution
with a T3aN0M0 high grade mucin-producing urachal adenocarcinoma.

Introduction
An urachus is a midline embryonic remnant structure within the space of Retzius that extends
superiorly from the anterior bladder dome toward the umbilicus. Prior to birth, the urachus
involutes to become the median umbilical ligament. Failure to regress can lead to various congenital
anomalies. In a minority of cases, urachal tract remnants undergo malignant transformation to
urachal cancer, a very rare cancer that represents 0.5% of bladder malignancies; of these, 85-90%
is adenocarcinomas [1]. Urachal adenocarcinomas have a 2:1 male predominance, and patients
typically present in midlife [1].
Urachal adenocarcinomas arise from metaplasia of urachal epithelium with subsequent
malignant transformation [1]. While there are multiple histological subtypes, 75-90% of these
tumors are mucin-secreting [1]. Due to their extraperitoneal location, these tumors tend to be
clinically silent for much of their course. When present, the most common manifestation is gross
hematuria. Prognosis is dependent on surgical margins and stage with the latter based on criteria set
forth by Sheldon et al. [2] (Table 1). More broadly, prognosis is relatively poor, as patients tend to
present later in the disease course [3].
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The mainstay of treatment is a partial cystectomy with en-bloc resection of the umbilicus
and urachal ligament with bilateral pelvic lymphadenectomy. While there is no definitive role for
neoadjuvant or adjuvant chemotherapy, there is some evidence that 5-FU and cisplatin combinations
may be helpful under special circumstances [3].
Imaging plays an increasingly large role in diagnosis and staging. Due to the rarity of urachal
adenocarcinomas, however, literature documenting characteristic imaging findings is limited. This
case report will highlight these imaging findings.

Case Presentation
A 43-year old male initially presented to an outside institution with gross hematuria, fatigue,
and dysuria. Physical examination was unremarkable, and urinalysis showed trace hematuria.
CT urogram showed a 3.4 cm x 2.9 cm peripherally calcified mass located superior to the bladder
dome without any significant enhancement. No suspicious lymphadenopathy or bony lesions were
noted. Cystoscopy was performed, showing a 2 cm mass near the bladder dome with calcification
and necrotic tissue consistent with malignancy. Pathologic results suggested transitional cell
adenocarcinoma.
Given the tumor’s location, this diagnosis was questioned, and reevaluation at our institution
suggested urachal adenocarcinoma. Repeat cystoscopy with mass and random bladder biopsies was
negative for any urothelial adenocarcinoma, consistent with urachal adenocarcinomas. [18F]FDG
PET showed no significant hypermetabolic activity within the bladder mass.
The patient underwent robotic-assisted laparoscopic partial cystectomy, umbilectomy,
and bilateral pelvic lymph node dissection. A 3.5 cm mass was resected from the bladder dome;
pathologic studies confirmed a high-grade mucin-producing urachal adenocarcinoma of signet cell
type. Surgical margins and biopsied lymph nodes were negative, staging the tumor at T3aN0M0.
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degree of hypermetabolism [6,7]. For example, this case yielded a
false-negative PET scan. The failure of PET to detect this patient’s
malignancy is not unexpected in the context of the tumor’s mucinous
pathology, a characteristic of 75-90% of urachal adenocarcinomas
[1]. It is well documented that mucinous adenocarcinomas are not as
[18F]FDG-avid as non-mucinous ones [8]. The abundant mucin that
they produce limits their cellularity, and thus, [18F]FDG uptake [8].
While there are no studies that specifically address the avidity of [18F]
FDG uptake in mucinous urachal adenocarcinomas, this limitation
observed for other mucinous tumors likely applies to those of urachal
origin.

Table 1: Sheldon Staging System for Urachal Carcinoma.
Stage I: No invasion beyond the urachal mucosa
Stage II: Invasion confined to the urachus
Stage III: Local extension into the:
Bladder (IIIA)
Abdominal wall (IIIB)
Peritoneum (IIIC)
Viscera other than the bladder (IIID)
Stage IV: Metastases to the:
Regional lymph nodes (IVA)

Furthermore, this patient’s tumor exhibits a central, unilocular
mucin distribution, restricting the thickness of the tumor’s walls. If
this thickness falls below the spatial resolution of the PET scanner,
there is loss of measured activity secondary to the partial-volume
effect. Additionally, irrespective of the tumor’s mucin production,
the activity of urachal adenocarcinomas and their progression into
adjacent structures can be difficult to evaluate due to their proximity
to the bladder, which appears hypermetabolic on PET secondary to
urinary [18F]FDG excretion.

Distant sites (IVB)

b

a
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As exemplified by this case, urachal adenocarcinomas have a
high potential to be PET negative. Consequently, PET’s role in their
work-up is limited. But, as not all urachal adenocarcinomas are
PET negative, PET has some utility in their work-up. Various cases
have reported mild or moderate [18F]FDG uptake for these tumors
[6,7]. Visual inspection of these cases suggests that patients with
metastatic disease and/or tumors with greater solid composition
are more likely to have elevated [18F]FDG uptake. This patient’s
tumor, in comparison, is not metastatic and does not exhibit a high
solid composition, making [18F]FDG uptake unlikely. While more
information is needed, it is reasonable for physicians to assess for
the presence/absence of these two variables and use this information
to help guide decision-making on the appropriateness of obtaining
PET in the work-up of urachal adenocarcinoma. For example, if a
patient’s CT shows urachal tumor with a significant solid component,
obtaining a PET scan is reasonable.

d

Figure 1: (a) Fused axial PET-CT slice showing peripherally calcified
urachal mass with minimal metabolic activity, isointense to background. (b
& c) non contrast enhanced CT slices in the same area showing the low
density urachal mass with peripheral stippled appearing calcifications. (d)
PET only image showing minimal to no discernable metabolic activity within
the urachal mass.

The patient underwent adjuvant chemotherapy with four cycles of
fluorouracil, gemcitabine, and cisplatin. To date, there has been no
evidence of residual or recurrent tumor (Figure 1).

Altogether, due to the high likelihood of false negative results,
PET imaging has an adjunct role in the work-up of urachal
adenocarcinomas. Rather, CT, with its pathognomonic findings, is
the modality of choice for these tumors.

Discussion
Despite there being no consensus regarding diagnostic criteria
for urachal adenocarcinomas, there are certain features that are
highly suggestive of their diagnosis, including: tumor location in the
bladder wall or dome; sharp demarcation between tumor and surface
bladder epithelium; and exclusion of primary adenocarcinomas
in another location [4]. While these criteria are useful in defining
urachal adenocarcinomas, their clinical utility can be improved with
the inclusion of comprehensive imaging findings, as most patients are
likely to undergo imaging as part of their work-up. The intent of this
case report is to showcase these findings.
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